BEDFORD, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 2, 2022, Anika granted non-statutory stock options (“Options”) covering an aggregate of 13,091 shares of common stock at a per share exercise price of $21.61, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, 16,113 Options at a per share exercise price of $23.77, which equaled 110% of the Closing Price on the grant date, and restricted stock units ( “RSUs”) covering an aggregate of 20,818 shares of common stock to 5 newly hired non-executive employees. Each grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.